AddThis Feed Button "Frequently Copied, Never Duplicated"

Showing posts with label Johnson and Johnson. Show all posts
Showing posts with label Johnson and Johnson. Show all posts

Thursday, June 07, 2012

J & J Mesh Bows Out of Mesh BIZ


If you are experiencing problems because of mesh please consider
looking  to our colleague, Linda Kilpatrick, for more information and support, 

Johnson & Johnson is stopping sales of surgical mesh products that aimed to relieve the intense pelvic pain of thousands of women but resulted in numerous reports of injury and several deaths.
The decision is the latest action by the health care giant tackling a range of problem products -- such as bottles of children's Tylenol and other popular over-the-counter medicines, as well as some contact lenses and certain hip implants -- that the company recalled due to manufacturing problems.
The surgical meshes, sold by J&J's Ethicon unit, are among a class of products made by various companies whose safety and effectiveness the Food and Drug Administration warned about in 2008. J&J's meshes are also subject to hundreds of product-liability lawsuits, according to a May securities filing by the company.
The company is planning to halt sales world-wide of Gynecare TVT Secur, Gynecare Prosima, Gynecare Prolift and Gynecare Prolift+M mesh products, an Ethicon spokesman said. The company has asked the FDA to allow it to keep selling its Gynecare Gynemesh product, but for insertion through the abdomen only, rather than the vagina as is also currently allowed, the spokesman said.
J&J will be stopping sales over the next three to nine months, with the goal of completing the process by the first quarter of 2013, the company spokesman said.
"This is not a product recall and we continue to have confidence in the safety and efficacy of these products. Our decision to discontinue these products is based on their commercial viability in light of changing market dynamics, and is not related to safety or efficacy," the Ethicon spokesman said in a statement.
The FDA didn't have an immediate comment.
Doctors began using surgical meshes in the 1970s to treat severe cases of a painful condition in which organs like the bladder, uterus or bowel drop down and protrude into a woman's vagina after childbirth. Initially, doctors inserted the meshes through the abdomen to support the organs. In the 1990s, gynecologists began inserting them through the vagina.
Between 2008 and 2010, the FDA received some 1,500 reports of adverse events for meshes made by J&J and other companies. In 2008, the FDA warned about complications including erosion, pain and urinary problems.
Reported June 6, 2012 in the Wall Street Journal
Selections from Natural Health News
Jan 07, 2012
Vaginal mesh repair has become popular, because of access to the areas involved in surgery, ease of application using the manufacturers' needles, variable mesh sizes that can be cut to size during surgery, laparotomy is not ...
Jan 05, 2012
This MESH crap is AWFUL! 2 years now, and will more and likely be lots more, I have suffered and had my whole life turned upside down. its the worst thing possible. What gets me is how long I have to wait to get this crap out ...
Jan 06, 2012
Democrats in the U.S. House of Representatives are calling for a congressional probe into a pair of high-profile medical device products – Lap-Bands and vaginal mesh – as Congress gears up for hearings and a vote on ...

Saturday, May 01, 2010

Another Recall for Tylenol and other medicines

UPDATE: 5 May -
FDA found bacteria in lots for recalled Tylenol
By MATTHEW PERRONE, AP Business Writer

WASHINGTON – Ingredients used by Johnson & Johnson in some of the 40 varieties of children's cold medicines recalled last week were contaminated with bacteria, according to a report by the Food and Drug Administration.

Agency officials said Tuesday none of the company's finished products tested positive for the contaminants, though such testing is not definitive.

"We think the risk to consumers at this point is remote," said Deborah Autor, director of FDA's drug compliance office, on a call with reporters.

The FDA report, which was posted online, lists more than 20 manufacturing problems found at the McNeil Consumer Healthcare plant in Fort Washington, Pa., where the formulas were made. The recalled products include children and infant formulations of Tylenol, Motrin, Zyrtec and Benadryl.

FDA inspectors visited the plant in mid-April and wrapped up their inspection Friday. J&J issued its "voluntary" recall later that night.

Among other problems, FDA inspectors said the company did not have laboratory facilities to test drug ingredients and failed to follow up on customer complaints.

J&J did not investigate more than 46 complaints received in the last year about "black or dark specks" in Tylenol products, according to the FDA's report.

Additionally, inspectors found some pieces of equipment covered with thick layers of dust, while others were held together with duct tape.

In a statement Tuesday, J&J called the problems cited by the FDA "unacceptable to us, and not indicative of how McNeil Consumer Healthcare intends to operate." The health conglomerate, which is based in New Brunswick, N.J., said production at the plant won't resume until the problems have been fixed.

The FDA reiterated that serious medical problems with the products are unlikely, but advised consumers to stop using the medicine as a precaution. Parents are instructed to use generic alternatives instead.

J&J's McNeil Consumer Healthcare unit has said some of the recalled medicines may have a higher concentration of the active ingredient than listed on the bottle. Others may contain particles, while still others may contain inactive ingredients that do not meet testing requirements.

FDA leadership told reporters Tuesday that they first met with J&J in February to discuss manufacturing problems identified in a warning letter about another J&J plant. The agency decided to step up inspections of the company's facilities based on those problems.

"That warning letter brought us to the point where we thought it was necessary to sit down with management and discuss our concerns," Autor said.

FDA officials said they are considering taking additional action against J&J, ranging from issuing more warning letters to pursuing criminal action.

Last week's sweeping recall, which involved products sold in the U.S. and 11 other countries, is the latest quality issue to taint J&J's over-the-counter medicine franchise. In January, the company recalled a line of adult Tylenol pain relievers due to complaints of a moldy smell associated with wooden pallets used to transport the drugs.
CAUTION: CHILDREN'S ZYRTEC - OR ANY OF THEIR SUGAR FREE PRODUCTS - CONTAINS SUCRALOSE (Splenda)

FDA Investigates Recall -WASHINGTON, Saturday May 1 – The Food and Drug Administration said Saturday it was investigating a health-care company for possible other problems following its recall of more than 40 over-the-counter infant's and children's liquid medications.

McNeil Consumer Healthcare Announces Voluntary Recall of Certain OTC Infants’ and Children's Products

Children's cold, allergy medicine recalled

Courtesy: Rense News Network

Saturday, April 10, 2010

Johnson & Johnson's Wild Spending Spree

Johnson & Johnson has an abysmal record of back door deals with a number of their drugs and nursing homes and Medicaid reimbursing programs. They don't seem to be stopping the money train around the Beltway. New rulings and legislation probably are giving them another go ahead as usual, but make sure you keep you eye on them.
Johnson & Johnson, the huge maker of health products from Band-Aids to biologic drugs, spent $1.64 million in the fourth quarter lobbying the government on issues related to the health care overhaul and on multiple bills that could affect its revenue, according to a recent disclosure form.

That was up 15 percent from the $1.44 million the New Brunswick, N.J.-based company spent lobbying in the year-ago period, but slightly less than the $1.66 million in spent in the third quarter of 2009. Read complete article
Lawsuit pending
B12 at Work
CO-Pay Comments
Don't Curb, Pull Ads